Crossmark

Bromocriptine Versus Levodopa and other treatments in Parkinson’s Disease: an updated Meta-analysis Involving more than 4000 patients across 12 randomized clinical trials

Crossref DOI link: https://doi.org/10.1007/s13760-024-02711-w

Published Online: 2024-12-24

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Afshar, Maziar

Sane, Negin

Moradi, Yousef
License Information

Text and Data Mining valid from 2024-12-24

Version of Record valid from 2024-12-24
More Information

Article History

Received: 13 July 2024

Accepted: 20 December 2024

First Online: 24 December 2024

Declarations

:

: The authors declare no competing interests.

: Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors. This article extracted from medical student thesis with Ethical Code “IR.MUK.

: Not applicable.

Document is current

Any future updates will be listed below